FDA Recalls Multiple Eye Drop Brands Over Sterility Concerns

More than 3.1 million bottles of over-the-counter eye drops, sold under 26 store and generic labels at some of the country's largest pharmacy and grocery chains, were pulled from the market after the manufacturer could not guarantee that its production process kept infection-causing microbes out of the product.

K.C. Pharmaceuticals, Inc., based in Pomona, California, voluntarily recalled the eye drop products, which had been distributed nationwide and sold under multiple brand names through major retailers including Walgreens, Kroger, CVS, H-E-B, Cardinal Health distributors, military exchanges, and other outlets. In total, more than 3.1 million bottles are impacted. The recall was initiated on March 3 and then classified on March 31.

The FDA designated it a Class II recall, its middle-tier classification. Under FDA definitions, a Class II recall describes "a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote."

The stated concern is a "lack of assurance of sterility," meaning K.C. Pharmaceuticals cannot guarantee that its manufacturing process prevented the introduction of infection-causing microbes. The recall spans products including those labeled "Artificial Tears," "Advanced Relief," and "Redness Lubricant" drops. Critically, the FDA's enforcement report did not explicitly state that any bottles were found to be contaminated, only that the standards required to ensure sterility were not met.

The recall affects 26 major labels, including generic and store brands sold at Walgreens, CVS, Rite Aid, Kroger, and Walmart. Among the specific brand names covered are Leader, Foster & Thrive, Good Sense, TopCare, DG Health, Equaline, CareOne, QC-Quality Choice, Geri Care, Exchange Select, Good Neighbor Pharmacy, and private-label products sold under Walgreens, CVS Health, Kroger, Publix, Meijer, and H-E-B store names. The recall is identified under multiple recall numbers, including D-0409-2026 through D-0416-2026, all associated with FDA Event ID 98533. Most affected lots carry expiration dates extending into May or October 2026, meaning bottles currently in medicine cabinets across the country could be part of the recall.

Anyone who has used these drops and experiences eye pain, redness, or changes in vision should seek medical attention. Specific lot numbers for each product line are listed in the FDA's enforcement report, which is searchable by product name and UPC. While the FDA has not outlined a specific refund process, major retailers are expected to honor returns or exchanges for the identified lots. Adverse reactions can be reported directly to the FDA's MedWatch program at 1-800-FDA-1088.

The scale of this recall raises pointed questions about how a single contract manufacturer's sterility lapse can quietly reach tens of millions of medicine cabinets before regulators act. K.C. Pharmaceuticals produced eye drops under at least 26 different retail labels, a common practice in the OTC pharmaceutical market where large chains outsource manufacturing to a handful of contract producers. No specific infections have been confirmed in connection with the affected products. But the breadth of the distribution network, stretching from national pharmacy chains to military exchanges and regional grocery brands, illustrates how deeply a single plant's quality failure can penetrate the consumer supply chain before a voluntary recall surfaces it.